Search

Search Constraints

You searched for: Author/Creator Wallace, Kori

Search Results

1. A Treat to Target Approach Decreases the Rate of CD‐Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM2017 ACG Governors Award for Excellence in Clinical Research: 598. (October 2017)

2. Adalimumab Therapy Achieves Clinical Remission and Response at Week 26 in Chinese Patients With Crohn's Disease: 1874. (October 2015)

3. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Issue 2 (23rd October 2019)

4. Early Symptom Improvement With Risankizumab Treatment in Patients With Moderately to Severely Active Crohn's Disease: Analysis From a Phase 2 Study: 834. (October 2019)

5. Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Issue 5 (20th October 2022)

6. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Issue 10114 (23rd December 2017)

7. Efficacy and Safety of Dose Escalation to Adalimumab 80 Mg Every Other Week in Japanese Patients With Crohn's Disease Who Lost Response to Maintenance Therapy: 1873. (October 2015)

8. Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. (2nd June 2021)

9. Long‐Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn's Disease: 3‐Year Interim Results From the Ongoing Phase 2 Open‐Label Extension Study: 806. (October 2019)

10. Operating Properties of Different Patient Reported Outcome Endpoints Combined With Endoscopic Evaluation: Data From EXTEND: 2259. (October 2015)